Drugs Against Calcitonin Gene-Related Peptide and its Receptor Used in the Treatment of Migraine: What are the New Progresses?
DOI:
https://doi.org/10.17140/NOJ-2-117Keywords:
Migraine; Calcitonin gene-related peptide.Abstract
Migraine is a chronic headache disorder that its exact pathomechanism is not very well
known but research in the last two decades indicates that it might be a brain disorder, a dismodulation of sensory processing of the brainstem responsible for regulation of vascular tone and
the pain. Several neurotransmitters and neuromodulators including neuropeptides have been
implicated in the pathomechanism of migraine, among them, Calcitonin gene-related peptide
(CGRP) has been the focus of many studies in recent years. Increased CGRP level (perhaps due
to release from peripheral and central sensory nerve endings) has been detected in the blood of
migraine patients and many basic and clinical investigators in recent years have been trying to
block the CGRP receptor by means of newly developed CGRP-receptor antagonist drugs or inhibit its activity by even newer compounds, the monoclonal Antibodies (mAbs) against CGRP
or its receptor. These latter ones are still in clinical trials but have had promising results so far
in alleviating the pain of migraine patients. This article will briefly review and discuss the role
of CGRP and its receptor in migraine and some of the other biological activities of CGRP, the
CGRP receptor antagonist drugs and the new progresses in mAbs against CGRP or its receptor.
References
Weiller C, May A, Limmroth V, et al. Brain stem activation in spontaneous human migraine attacks. Nat. Med. 1995; 1: 658- 660.
Akerman S, Holland PR, Goadsby PJ. Diencephalic and brainstem mechanisms in migraine. Nat Rev Neurosci. 2011; 12: 570-584. doi: 10.1038/nrn3057
Cohen AS, Goadsby PJ. Functional neuroimaging of primary headache disorders. Expert Rev. Neurother. 2006; 6: 1159-1171. doi: 10.1586/14737175.6.8.1159
Goadsby PJ. Recent advances in understanding migraine mechanisms, molecules and therapeutics. Trends Mol. Med. 2007; 13: 39-44. doi: 10.1016/j.molmed.2006.11.005
Samsam M. Central nervous system acting drugs in treatment of migraine headache. Cent Nerv Syst Agents Med Chem. 2012; 12(3): 158-172. doi: 10.2174/187152412802430147
Lazarov NE. Comparative analysis of the chemical neuroanat-omy of the mammalian trigeminal ganglion and mesencephalic trigeminal nucleus. Prog Neurobiol. 2002; 66(1): 19-59. doi: 10.1016/S0301-0082(01)00021-1
Samsam M, Coveñas R, Ahangari R, Yajeya J. Major neu-roanatomical and neurochemical substrates involved in primary headaches. Chapter 1. Neuroanatomy Research Advances; In: Flynn CE, Callaghan BR, eds. Nova Science Publishers; New York; 2009: 1- 58.
Samsam M, Coveñas R, Ahangari R, Yajeya J, Narváez JA, Tramu G. Simultaneous depletion of neurokinin A, substance P and calcitonin gene related peptide immunoreactivities in the caudal trigeminal nucleus of the rat following electrical stimula-tion of the Gasserian ganglion: a possible co-release of neuro-peptides. PAIN. 2000; 84: 389-395.
Friberg L, Olesen J, Olsen TS, Karle A, Ekman R, Fahrenkrug J. Absence of vasoactive peptide release from brain to cerebral circulation during onset of migraine with aura. Cephalalgia. 1994; 14(1): 47-54. doi: 10.1046/j.1468-2982.1994.1401047.x
Gallai V, Sarchielli P, Floridi A. et al. Vasoactive peptide lev-els in the plasma of young migraine patients with and without aura assessed both interictally and ictally. Cephalalgia. 1995; 15(5): 384-390. doi: 10.1046/j.1468-2982.1995.1505384.x
Lassen LH, Haderslev PA, Jacobsen VB, Iversen HK, Sperling B, Olesen J. CGRP may play a causative role in mi-graine. Cephalalgia. 2002; 22(1): 54-61. doi: 10.1046/j.1468- 2982.2002.00310.x
Olesen J, Diener HC, Husstedt IW, et al. BIBN 4096 BS Clinical Proof of Concept Study Group. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treat-ment of migraine. N Engl J Med. 2004; 350(11): 1104-1110.
Evers S, Afra J, Frese A, et al. EFNS guideline on the drug treatment of migraine-revised report of an EFNS task force. Eur. J. Neurol. 2009; 16: 968-981. doi: 10.1111/j.1468- 1331.2009.02748.x
Humphrey PP. The discovery and development of the trip-tans, a major therapeutic breakthrough. Headache. 2008; 48: 685-687. doi: 10.1111/j.1526-4610.2008.01097.x
Bigal ME, Krymchantowski AV, Ho T. Migraine in the trip-tan era: progresses achieved, lessons learned and future develop-ments. Arq. Neuropsiquiatr. 2009; 67: 559-569. doi: 10.1590/ S0004-282X2009000300040
Ferrari MD, Färkkilä M, Reuter U, European COL-144 Investigators. Acute treatment of migraine with the selec-tive 5-HT1F receptor agonist lasmiditan-a randomised proof-of-concept trial. Cephalalgia. 2010; 30: 1170-1178. doi: 10.1177/0333102410375512
Samsam M, Coveñas R, Ahangari R, Yajeya J. Neuropeptides and other chemical mediators, and the role of anti-inflammatory drugs in primary headaches. AIAA-MC. 2010; 3: 170-188.
Amara SG, Jonas V, Rosenfeld MG, Ong ES, Evans RM. Alternative RNA processing in calcitonin gene expression gen-erates mRNAs encoding different polypeptide products. Nature. 1982; 298: 240-244. doi: 10.1038/298240a0
Brain SD, MacIntyre I, Williams TJ. A second form of human calcitonin gene-related peptide which is a potent vasodilator. Eur J Pharmacol. 1986; 124(3): 349-352. doi: 10.1016/0014- 2999(86)90238-4
Sternini C, Anderson K. Calcitonin gene-related peptide-containing neurons supplying the rat digestive system: differ-ential distribution and expression pattern. Somatosens Mot Res. 1992; 9(1): 45-59.
Ohno T, Hattori Y, Komine R, et al. Roles of calcitonin gene-related peptide in maintenance of gastric mucosal integrity and in enhancement of ulcer healing and angiogenesis. Gastroenter-ology. 2008; 134(1): 215-225. doi: 10.1053/j.gastro.2007.10.001
Durham PL, Vause CV. Calcitonin gene-related peptide (CGRP) receptor antagonists in the treatment of migraine. CNS Drugs. 2010; 24(7): 539-548.
van Rossum D, Hanisch UK, Quirion R. Neuroanatomical localization, pharmacological characterization and functions of CGRP, related peptides and their receptors. Neurosci Biobehav Rev. 1997; 21(5): 649-678.
Brain SD, Williams TJ, Tippins JR, Morris HR, MacIntyre I. Calcitonin gene-related peptide is a potent vasodilator. Nature. 1985; 313: 54-56.
Burstein R, Yarnitsky D, Goor-Aryeh I, Ransil BJ, Bajwa ZH. An association between migraine and cutaneous allodynia. Ann. Neurol. 2000; 47: 614-624.
Villalón CM, Centurión D, Valdivia LF, De Vries P, Sax-ena PR. An introduction to migraine: from ancient treatment to functional pharmacology and antimigraine therapy. Proc. West Pharmacol. Soc. 2002; 45: 199-210.
Spierings ELH. Pathogenesis of the migraine attack. Clin. J. Pain. 2003; 19: 255-262.
Silberstein SD. Migraine pathophysiology and its clinical implications. Cephalalgia. 2004: 2: 2-7.
Kruuse C, Thomsen L, Birk S, Olesen J. Migraine can be induced by sildenafil without changes in middle cerebral artery diameter. Brain, 2003; 126: 241-247.
Nichols FT 3rd, Mawad M, Mohr JP, Stein B, Hilal S, Mi-chelsen WJ. Focal headache during balloon inflation in the in-ternal carotid and middle cerebral arteries. Stroke. 1990; 21(4): 555-559. doi: 10.1161/01.STR.21.4.555
Olesen J, Friberg L, Olsen TS, et al. Timing and topography of cerebral blood flow, aura, and headache during migraine at-tacks. Ann Neurol. 1990; 28(6): 791-798.
May A, Büchel C, Turner R, Goadsby PJ. Magnetic reso-nance angiography in facial and other pain: neurovascular mechanisms of trigeminal sensation. J Cereb Blood Flow Metab. 2001; 21(10): 1171-1176. doi: 10.1097/00004647-200110000- 00005
McLatchie LM, Fraser NJ, Main MJ, et al. RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor. Nature. 1998; 393: 333-339. doi: 10.1038/30666
Choksi T, Hay DL, Legon S, et al. Comparison of the expres-sion of calcitonin receptor-like receptor (CRLR) and receptor activity modifying proteins (RAMPs) with CGRP and adreno-medullin binding in cell lines. Br J Pharmacol. 2002; 136(5): 784-792. doi: 10.1038/sj.bjp.0704761
Poyner DR, Sexton PM, Marshall I, et al. International Union of Pharmacology. XXXII. The mammalian calcitonin gene-related peptides, adrenomedullin, amylin, and calcitonin receptors. Pharmacol Rev. 2002; 54(2): 233-246.
Miller PS, Barwell J, Poyner DR, Wigglesworth MJ, Garland SL, Donnelly D. Non-peptidic antagonists of the CGRP recep-tor, BIBN4096BS and MK-0974, interact with the calcitonin receptor-like receptor via methionine-42 and RAMP1 via trypto-phan-74. Biochem. Biophys. Res. Commun. 2010; 391: 437-442. doi: 10.1016/j.bbrc.2009.11.076
Mallee JJ, Salvatore CA, LeBourdelles B, et al. Receptor activity-modifying protein 1 determines the species selectivity of non-peptide CGRP receptor antagonists. J Biol Chem. 2002; 277(16): 14294-14298. doi: 10.1074/jbc.M109661200
Zhang Z, Winborn CS, Marquez de Prado B, Russo AF. Sen-sitization of calcitonin gene-related peptide receptors by recep-tor activity-modifying protein-1 in the trigeminal ganglion. J. Neurosci., 2007; 27: 2693-2703.
Hay DL, Howitt SG, Conner AC, Doods H, Schindler M, Poyner DR. A comparison of the actions of BIBN4096BS and CGRP(8-37) on CGRP and adrenomedullin receptors expressed on SK-N-MC, L6, Col 29 and Rat 2 cells. Br J Pharmacol. 2002; 137(1): 80-86.
Dennis T, Fournier A, Cadieux A, et al. hCGRP8-37, a calci-tonin gene-related peptide antagonist revealing calcitonin gene-related peptide receptor heterogeneity in brain and periphery. J. Pharmacol. Exp. Ther. 1990; 254: 123-128.
Hay DL, Poyner DR, Quirion R, et al. International Union of Pharmacology. International Union of Pharmacology. LXIX. Status of the calcitonin gene-related peptide subtype 2 receptor. Pharmacol. Rev. 2008; 60: 143-145. doi: 10.1124/pr.108.00372
Kitazono T, Heistad DD, Faraci FM. Role of ATP-sensitive K+ channels in CGRP-induced dilatation of basilar artery in vivo. Am J Physiol. 1993; 265(2 Pt 2): H581-H585.
Hong KW, Yoo SE, Yu SS, Lee JY, Rhim BY. Pharmaco-logical coupling and functional role for CGRP receptors in the vasodilation of rat pial arterioles. Am J Physiol. 1996; 270(1 Pt 2): H317-H323.
Birk S, Kruuse C, Petersen KA, Tfelt-Hansen P, Olesen J. The headache-inducing effect of cilostazol in human volunteers. Cephalalgia. 2006; 26(11): 1304-1309. doi: 10.1111/j.1468- 2982.2006.01218.x
Bellamy J, Bowen EJ, Russo AF, Durham PL. Nitric oxide regulation of calcitonin gene-related peptide gene expression in rat trigeminal ganglia neurons. Eur J Neurosci. 2006; 23(8): 2057-2066. doi: 10.1111/j.1460-9568.2006.04742.x
Eftekhari S, Gaspar RC, Roberts R, et al. Localization of CGRP receptor components and receptor binding sites in rhe-sus monkey brainstem: a detailed study using in situ hybridiza-tion, immunofluorescence and autoradiography. J Comp Neurol. 2015. doi: 10.1002/cne.23828
Edvinsson L, Eftekhari S, Salvatore CA, Warfvinge K. Cer-ebellar distribution of calcitonin gene-related peptide (CGRP) and its receptor components calcitonin receptor-like receptor (CLR) and receptor activity modifying protein 1 (RAMP1) in rat. Mol Cell Neurosci. 2011; 46(1): 333-339. doi: 10.1016/j. mcn.2010.10.005
Ottosson A, Edvinsson L. Release of histamine from du-ral mast cells by substance P and calcitonin gene-related pep-tide. Cephalalgia. 1997; 17(3): 166-174. doi: 10.1046/j.1468- 2982.1997.1703166.x
Lennerz JK, Rühle V, Ceppa EP, et al. Calcitonin recep-tor-like receptor (CLR), receptor activity-modifying protein 1 (RAMP1), and calcitonin gene-related peptide (CGRP) immu-noreactivity in the rat trigeminovascular system: differences between peripheral and central CGRP receptor distribution. J Comp Neurol. 2008; 507(3): 1277-1299. doi: 10.1002/cne.21607
Yu LC, Zheng EM, Lundeberg T. Calcitonin gene-related peptide 8-37 inhibits the evoked discharge frequency of wide dynamic range neurons in dorsal horn of the spinal cord in rats. Regul Pept. 1999; 83(1): 21-24. doi: 10.1016/S0167- 0115(99)00046-4
Benemei S, De Cesaris F, Fusi C, Rossi E, Lupi C, Gep-petti P. TRPA1 and other TRP channels in migraine. J Headache Pain. 2013; 14: 71.
Reddington M, Priller J, Treichel J, Haas C, Kreutzberg GW. Astrocytes and microglia as potential targets for calcitonin gene related peptide in the central nervous system. Can J Physiol Pharmacol. 1995; 73(7): 1047-1049.
Arulmani U, Gupta S, Massen Van Den Brink AM, Centurión D, Villalón CM, Saxena PR. Experimental migraine models and their relevance in migraine therapy. Cephalalgia, 2006; 26: 642- 659. doi: 10.1111/j.1468-2982.2005.01082.x
Linde M. Migraine: a review and future directions for treat-ment. Acta Neurol. Scand., 2006; 114: 71-83. doi: 10.1111/j.1600- 0404.2006.00670.x
Edvinsson L, Alm R, Shaw D, et al. Effect of the CGRP receptor antagonist BIBN4096BS in human cerebral, coronary and omental arteries and in SK-N-MC cells. Eur J Pharmacol. 2002; 434: 49-53. doi: 10.1016/S0014-2999(01)01532-1
Jansen-Olesen I, Jorgensen L, Engel U, Edvinsson L. In-depth characterization of CGRP receptors in human intracranial arteries. Eur. J. Pharmacol., 2003; 481: 207-216. doi: 10.1016/j. ejphar.2003.09.021
Wu D, Eberlein W, Rudolf K, Engel W, Hallermayer G, Doods H. Characterisation of calcitonin gene-related peptide re-ceptors in rat atrium and vas deferens: evidence for a [Cys(Et)(2, 7)]hCGRP-preferring receptor. Eur. J. Pharmacol. 2000; 400: 313-319. doi: 10.1016/S0014-2999(00)00407-6
Jansen-Olesen I, Kaarill L, Edvinsson L. Characteriza-tion of CGRP(1) receptors in the guinea pig basilar artery. Eur. J. Pharmacol. 2001; 414: 249-258. doi: 10.1016/S0014- 2999(01)00760-9
Wu D, Doods H, Arndt K, Schindler M. Development and potential of non-peptide antagonists for calcitonin-gene-related peptide (CGRP) receptors: evidence for CGRP receptor hetero-geneity. Biochem Soc Trans. 2002; 30: 468-473. doi: 10.1042/ bst0300468
Gupta S, Akerman S, van den Maagdenberg AM, Saxena PR, Goadsby PJ, van den Brink AM. Intravital microscopy on a closed cranial window in mice: a model to study trigeminovas-cular mechanisms involved in migraine. Cephalalgia. 2006, 26, 1294-303.
Petersen KA, Birk S, Lassen LH, et al. The CGRP-antag-onist, BIBN4096BS does not affect cerebral or systemic hae-modynamics in healthy volunteers. Cephalalgia. 2005; 25: 139- 147. doi: 10.1111/j.1468-2982.2004.00830.x
Tröltzsch M, Denekas T, Messlinger K. The calcitonin gene-related peptide (CGRP) receptor antagonist BIBN4096BS re-duces neurogenic increases in dural blood flow. Eur J Pharma-col. 2007; 562: 103-110. doi: 10.1016/j.ejphar.2007.01.058
Gupta S, Mehrotra S, Villalon CM, et al. Characterisation of CGRP receptors in human and porcine isolated coronary arter-ies: evidence for CGRP receptor heterogeneity. Eur J Pharma-col. 2006; 530: 107-116. doi: 10.1016/j.ejphar.2005.11.020
Hasbak P, Saetrum Opgaard O, Eskesen K, et al. Investi-gation of CGRP receptors and peptide pharmacology in human coronary arteries. Characterization with a nonpeptide antago-nist. J. Pharmacol. Exp. Ther. 2003; 304: 326-333. doi: 10.1124/ jpet.102.037754
Sixt ML, Messlinger K, Fischer MJ. Calcitonin gene-related peptide receptor antagonist olcegepant acts in the spinal trigemi-nal nucleus. Brain. 2009; 132: 3134-3141. doi: 10.1093/brain/ awp168
Ho TW, Mannix LK, Fan X, et al. MK-0974 Protocol 004 study group. Collaborators (20), Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine. Neurology. 2008; 70: 1304-1312.
Connor K.M, Shapiro RE, Diener HC, et al. Random-ized, controlled trial of telcagepant for the acute treatment of migraine. Neurology. 2009; 73: 970-977. doi: 10.1212/ WNL.0b013e3181b87942
Iovino M, Feifel U, Yong CL, Wolters JM, Wallenstein G. Safety, tolerability and pharmacokinetics of BIBN 4096 BS, the first selective small molecule calcitonin gene-related peptide receptor antagonist, following single intravenous administra-tion in healthy volunteers. Cephalalgia. 2004; 24: 645-656. doi: 10.1111/j.1468-2982.2004.00726.x
Ho TW, Ferrari MD, Dodick DW, et al. Efficacy and toler-ability of MK-0974 (telcagepant), a new oral antagonist of calci-tonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial. Lancet. 2008, 372: 2115-2123. doi: 10.1016/ S0140-6736(08)61626-8
Summ O, Charbit AR, Andreou AP, Goadsby PJ. Modulation of nocioceptive transmission with calcitonin gene-related pep-tide receptor antagonists in the thalamus. Brain. 2010; 133(9): 2540-2548. doi: 10.1093/brain/awq224
Tepper SJ, Cleves C. Telcagepant, a calcitonin gene-related peptide antagonist for the treatment of migraine. Curr. Opin. In-vestig. Drugs. 2009; 10: 711-720.
Tfelt-Hansen P, Olesen J. Possible site of action of CGRP antagonists in migraine. Cephalalgia. 2011; 31: 748-750. doi: 10.1177/0333102411398403
Diener HC, Barbanti P, Dahlöf C, Reuter U, Habeck J, Pod-horna J. BI 44370 TA, an oral CGRP antagonist for the treatment of acute migraine attacks: results from a phase II study. Cepha-lalgia. 2011; 31(5): 573-584. doi: 10.1177/0333102410388435
Benemei S, Nicoletti P, Capone JA, Geppetti P. Pain phar-macology in migraine: focus on CGRP and CGRP receptors. Neurol. Sci., 2007, 28(Suppl 2): S89-S93. doi: 10.1007/s10072- 007-0757-5
Villalón CM, Olesen J. The role of CGRP in the pathophysi-ology of migraine and efficacy of CGRP receptor antagonists as acute antimigraine drugs. Pharmacol. Ther., 2009; 124: 309- 323. doi: 10.1016/j.pharmthera.2009.09.003
Karsan N, Goadsby PJ. Calcitonin gene-related peptide and migraine. Curr Opin Neurol. 2015; 28(3): 250-254.
Karsan N, Goadsby PJ. CGRP mechanism antagonists and migraine management. Curr Neurol Neurosci Rep. 2015; 15(5): 25.
Hougaard A, Tfelt-Hansen P. Review of dose-response curves for acute antimigraine drugs: triptans, 5-HT1F agonists and CGRP antagonists. Expert Opin Drug Metab Toxicol. 2015; 22: 1-10.
Hoffmann J, Goadsby PJ. New agents for acute treatment of migraine: CGRP receptor antagonists, iNOS Inhibitors. Curr Treat Options Neurol. 2012; 14(1): 50-59. doi: 10.1007/s11940- 011-0155-4
Tajti J, Csáti A, Vécsei L. Novel strategies for the treatment of migraine attacks via the CGRP, serotonin, dopamine, PAC1, and NMDA receptors. Expert Opin Drug Metab Toxicol. 2014; 10(11): 1509-1520.
Edvinsson L. CGRP receptor antagonists and antibodies against CGRP and its receptor in migraine treatment. Br J Clin Pharmacol. 2015; 80(2): 193-199. doi: 10.1111/bcp.12618
Bigal ME, Walter S, Rapoport AM. Therapeutic antibodies against CGRP or its receptor. Br J Clin Pharmacol. 2015; 79(6): 886-895. doi: 10.1111/bcp.12591
Bigal ME, Walter S. Monoclonal antibodies for migraine: preventing calcitonin gene-related peptide activity. CNS Drugs. 2014; 28(5): 389-399. doi: 10.1007/s40263-014-0156-4
Reuter U. Anti-CGRP antibodies: a new approach to mi-graine prevention. Lancet Neurol. 2014; 13(9): 857-859. doi: 10.1016/S1474-4422(14)70126-7
Burton DR. Antibodies, viruses and vaccines. Nat Rev Im-munol. 2002; 2(9): 706-713. doi: 10.1038/nri891
Nimmerjahn F, Gordan S, Lux A. FcγR dependent mecha-nisms of cytotoxic, agonistic, and neutralizing antibody activi-ties. Trends Immunol. 2015; 36(6): 325-336.
Bigal ME, Walter S, Rapoport AM. Calcitonin gene-related peptide (CGRP) and migraine current understanding and state of development. Headache. 2013; 53(8): 1230-1244. doi: 10.1111/ head.12179
Alder Biopharmaceuticals, Inc. A parallel group, double-blind, randomized, placebo controlled dose-ranging phase 2 trial to evaluate the efficacy, safety, and pharmacokinetics of ALD403 administered intravenously in patients with chronic migraine. http://www.alderbio.com/clinical-trials/ 2013; Ac-cessed August, 2015.
Alder Biopharmaceuticals, Inc. Safety tolerabil-ity and pharmacokinetics of ALD403. Available at: https://clinicaltrials.gov/ct2/show/NCT01579383?term= ALD403&rank=1 2013; Accessed August, 2015.
Alder Biopharmaceuticals, Inc. Safety, effica-cy and pharmacokinetics of ALD403. Available at: https://clinicaltrials.gov/ct2/show/NCT01772524?term =ALD403&rank=3 2014; Accessed August, 2015.
Alder Biopharmaceuticals, Inc. A multicenter as-sessment of ALD403 in chronic migraine. https://clini-c a l t r i a l s . g o v / c t 2 / s h o w / N C T 0 2 2 7 5 11 7 ? t e r m = A L D 403&rank=2 2015; Accessed August, 2015.
Dodick DW, Goadsby PJ, Silberstein SD, et al. ALD403 study investigators. Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-con-trolled, exploratory phase 2 trial. Lancet Neurol. 2014; 13(11): 1100-1107. doi: 10.1016/S1474-4422(14)70209-1
Eli Lilly and Company. CGRP mAb migraine prevention. Available at: http://www.lilly.com/SiteCollectionDocuments/ Pipeline/Clinical%20Development%20Pipeline/10.html. Ac-cessed in Aug 2015.
Dodick DW, Goadsby PJ, Spierings EL, Scherer JC, Swee-ney SP, Grayzel DS. Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study. Lancet Neurol. 2014; 13(9): 885-892. doi: 10.1016/S1474-4422(14)70128-0
Eli Lilly and Company. A study of LY2951742 in healthy Japanese and Caucasian participants. Available at: https://clini-caltrials.gov/ct2/show/NCT02104765?term=LY2951742&ra nk=2 2015; Accessed August, 2015.
Eli Lilly and Compan. A study of LY2951742 in healthy volunteers. Available at: https://clinicaltrials.gov/ct2/show/NCT 01337596?term=LY2951742&rank=5 2015; Accessed August, 2015.
Eli Lilly and Company. A study of LY2951742 in partici-pants with migraine. Available at: https://clinicaltrials.gov/ct2/ show/NCT01625988?term=LY2951742&rank=7 2015; Ac-cessed August, 2015.
Vermeersch S, Benschop RJ, Van Hecken A, et al. Trans-lational pharmacodynamics of CGRP monoclonal antibody LY2951742 in a capsaicin-induced dermal blood flow model. J Pharmacol Exp Ther. 2015; 354(3): 350-357.
Eli Lilly and Company. A Study of LY2951742 in Partici-pants With Chronic Cluster Headache. Available at: https://clini-caltrials.gov/ct2/show/NCT02438826?term=LY2951742&ra nk=3 2015; Accessed August, 2015.
Teva to Present New Findings at the American Headache Society (AHS) Meeting – Analysis of Migraine Phase IIb Stud-ies Provides Novel Insights into TEV-48125 Efficacy and Safe-ty in Both Episodic & Chronic Migraine. Available at: http:// news.tevausa.com/mobile.view?c=251945&v=203&d=1& id=2060482, 2015.
Schuster NM, Vollbracht S, Rapoport AM. Emerging treat-ments for the primary headache disorders. Neurol Sci. 2015; 36(Suppl 1): 109-113.
Walter S, Bigal ME. TEV-48125: a review of a monoclonal CGRP antibody in development for the preventive treatment of migraine. Curr Pain Headache Rep. 2015; 19(3): 6.
Walter S, Alibhoy A, Escandon R, Bigal ME. Evaluation of cardiovascular parameters in cynomolgus monkeys following IV administration of LBR-101, a monoclonal antibody against calcitonin gene-related peptide. MAbs. 2014; 6(4): 871-878.
Bigal ME, Escandon R, Bronson M, et al. Safety and tol-erability of LBR-101, a humanized monoclonal antibody that blocks the binding of CGRP to its receptor: Results of the Phase 1 program. Cephalalgia. 2013; 34(7): 483-492.
TEVA latest news. Available at: http://www.tevapharm. com/news/?itemid=%7B007EDCEC-98E8-41EA-8775- 2F4E78BB12E6%7D 2015; Accessed 2015.
Amgen. Amgen To Present AMG 334 Data At 17th Con-gress of the International Headache Society: Data Evaluating Safety and Efficacy of AMG 334 Provides New Insights Into Preventive Treatment of Migraine. Available at: http://wwwext. amgen.com/media/media_pr_detail.jsp?year=2015&release ID=2046668. Accessed August, 2015.
Amgen. Ascending single doses of AMG 334 in healthy subjects and migraine patients. Available at: https://clinicaltrials. gov/ct2/show/NCT01688739?term=AMG+334&rank=1 2014; Accessed August, 2015.
Amgen. Ascending multiple-doses of AMG 334 in healthy subjects and in Migraine Patients. Available at: https://clinical-trials.gov/ct2/show/NCT01723514?term=AMG+334&rank=3 2013; Accessed August, 2015.
Amgen. Ascending multiple-doses of AMG 334 in healthy subjects and in migraine patients. Available at: http://www.am-gentrials.com/amgen/trialsummary.aspx?studyid=20101268. Accessed August, 2015.
Amgen. A phase 2 study to evaluate the efficacy and safety of AMG 334 in migraine prevention. Available at: https://clinical-trials.gov/ct2/show/NCT01952574?term=AMG+334&rank=2 2015; Accessed August, 2015.
Amgen. A sudy to evaluate the efficacy and safety of AMG 334 in chronic migraine prevention. Available at: http://www. amgentrials.com/amgen/trialsummary.aspx?studyid=20120295 2015; Accessed August, 2015.
Amgen. A study to assess the long-term safety and ef-ficacy of AMG 334 in chronic migraine prevention. Avail-able at: http://www.amgentrials.com/amgen/trialsummary. aspx?studyid=20130255 2015; Accessed August, 2015.
Amgen. Amgen Presents Open-Label Extension Data From Ongoing Phase 2 Study Of AMG 334 In The Prevention Of Epi-sodic Migraine. Available at: http://wwwext.amgen.com/media/ media_pr_detail.jsp?year=2015&releaseID=2061044 2015; Accessed September, 2015.
PRNewswire/THOUSAND OAKS, Calif. Amgen presents first phase 2 data for AMG 334 in the Prevention of Episodic Migraine. Available at: http://www.prnewswire.com/news-re-leases/amgen-presents-first-phase-2-data-for-amg-334-in-the-prevention-of-episodic-migraine-300084005.html 2015; Ac-cessed May 15, 2015.
PRNewswire/ THOUSAND OAKS, Calif. Amgen Pres-ents open-label extension data from ongoing phase 2 study of amg 334 in the prevention of episodic migraine: Avail-able at: http://wwwext.amgen.com/media/media_pr_detail. jsp?year=2015&releaseID=2061044 2015; Accessed June 19, 2015.
Nohr D, Weihe E. The neuroimmune link in the bronchus-associated lymphoid tissue (BALT) of cat and rat: peptides and neural markers. Brain Behav Immun. 1991; 5(1): 84-101.
Keith IM. The role of endogenous lung neuropeptides in regulation of the pulmonary circulation. Physiol Res. 2000; 49(5): 519-537.
Dakhama A, Larsen GL, Gelfand EW. Calcitonin gene-re-lated peptide: role in airway homeostasis. Curr Opin Pharma-col. 2004; 4(3): 215-220.
Okajima K, Harada N. Regulation of inflammatory re-sponses by sensory neurons: molecular mechanism(s) and pos-sible therapeutic applications. Curr Med Chem. 2006; 13(19): 2241-2251.
Springer J, Geppetti P, Fischer A, Groneberg DA. Calcito-nin gene-related peptide as inflammatory mediator. Pulm Phar-macol Ther. 2003; 16(3): 121-130.
Holzmann B. Antiinflammatory activities of CGRP modu-lating innate immune responses in health and disease. Curr Pro-tein Pept Sci. 2013; 14(4): 268-274.
Alpaerts K, Buckinx R, Adriaensen D, Van Nassauw L, Timmermans JP. Identification and putative roles of distinct sub-types of intestinal dendritic cells in neuroimmune communica-tion: what can be learned from other organ systems? Anat Rec (Hoboken). 2015; 298(5): 903-916. doi: 10.1002/ar.23106
Assas BM, Miyan JA, Pennock JL. Cross-talk between neural and immune receptors provides a potential mechanism of homeostatic regulation in the gut mucosa. Mucosal Immunol. 2014; 7(6): 1283-1289. doi: 10.1038/mi.2014.80
Evangelista S. Capsaicin receptor as target of calcitonin gene-related peptide in the gut. Prog Drug Res. 2014; 68: 259- 276. doi: 10.1007/978-3-0348-0828-6_10
Taché Y, Garrick T, Raybould H. Central nervous system action of peptides to influence gastrointestinal motor function. Gastroenterology. 1990; 98(2): 517-528.
Demir IE, Schäfer KH, Tieftrunk E, Friess H, Ceyhan GO. Neural plasticity in the gastrointestinal tract: chronic inflam-mation, neurotrophic signals, and hypersensitivity. Acta Neuro-pathol. 2013; 125(4): 491-509. doi: 10.1007/s00401-013-1099-4
Gaete PS, Lillo MA, Figueroa XF. Functional role of con-nexins and pannexins in the interaction between vascular and nervous system. J Cell Physiol. 2014; 229(10): 1336-1345. doi: 10.1002/jcp.24563
Reuss S. Trigeminal innervation of the mammalian pi-neal gland. Microsc Res Tech. 1999; 46(4-5): 305-309. doi: 10.1002/(SICI)1097-0029(19990815/01)46:4/5<305::AID-JEMT7>3.0.CO;2-#
Vega AV, Avila G. CGRP, a vasodilator neuropeptide that stimulates neuromuscular transmission and EC cou-pling. Curr Vasc Pharmacol. 2010; 8(3): 394-403. doi: 10.2174/157016110791112287
Ishida K, Kawamata T, Tanaka S, Shindo T, Kawamata M. Calcitonin gene-related peptide is involved in inflammatory pain but not in postoperative pain. Anesthesiology. 2014; 121(5): 1068-1079. doi: 10.1097/ALN.0000000000000364
Nelson KB, Grether JK, Croen LA, et al. Neuropeptides and neurotrophins in neonatal blood of children with autism or mental retardation. Ann Neurol. 2001; 49: 597-606.
McNamara IM, Borella AW, Bialowas LA, Whitaker-Azmitia PM. Further studies in the developmental hypersero-tonemia model (DHS) of autism: social, behavioral and peptide changes. Brain Res. 2008; 1189: 203-214.
Gabriele S, Sacco R, Persico AM. Blood serotonin levels in autism spectrum disorder: a systematic review and meta-anal-ysis. Eur Neuropsychopharmacol. 2014; 24(6): 919-929. doi: 10.1016/j.euroneuro.2014.02.004
Yang CJ, Tan HP, Du YJ. The developmental disruptions of serotonin signaling may involved in autism during early brain development. Neuroscience. 2014; 267: 1-10. doi: 10.1016/j. neuroscience.2014.02.021
Miles JH. Autism spectrum disorders--a genetics re-view. Genet Med. 2011; 13(4): 278-294. doi: 10.1097/ GIM.0b013e3181ff67ba
Samsam M, Ahangari R, Naser SA. Pathophysiology of au-tism spectrum disorders: revisiting gastrointestinal involvement and immune imbalance. World J Gastroenterol. 2014; 20(29): 9942-9951. doi: 10.3748/wjg.v20.i29.9942
White JF. Intestinal pathophysiology in autism. Exp Biol Med (Maywood). 2003; 228: 639-649.
Chaidez V, Hansen RL, Hertz-Picciotto I. Gastrointestinal problems in children with autism, developmental delays or typi-cal development. J Autism Dev Disord. 2014; 44(5): 1117-1127. doi: 10.1007/s10803-013-1973-x
Mazefsky CA, Schreiber DR, Olino TM, Minshew NJ. The association between emotional and behavioral prob-lems and gastrointestinal symptoms among children with high-functioning autism. Autism. 2014; 18(5): 493-501. doi: 10.1177/1362361313485164
Buie T, Campbell DB, Fuchs GJ 3rd, et al. Evaluation, diag-nosis, and treatment of gastrointestinal disorders in individuals with ASDs: a consensus report. Pediatrics. 2010; 125(Suppl 1): S1-S18. doi: 10.1542/peds.2009-1878C
Mazurek MO, Vasa RA, Kalb LG, et al. Anxiety, senso-ry over-responsivity, and gastrointestinal problems in children with autism spectrum disorders. J Abnorm Child Psychol. 2013; 41(1): 165-176. doi: 10.1007/s10802-012-9668-x
Mikami N, Watanabe K, Hashimoto N, et al. Calcitonin gene-related peptide enhances experimental autoimmune en-cephalomyelitis by promoting Th17-cell functions. Int Immunol. 2012; 24(11): 681-691. doi: 10.1093/intimm/dxs075
Jusek G, Reim D, Tsujikawa K, Holzmann B. Deficiency of the CGRP receptor component RAMP1 attenuates immunosup-pression during the early phase of septic peritonitis. Immunobi-ology. 2012; 217(8): 761-767. doi: 10.1016/j.imbio.2012.04.009
Park SH, Sim YB, Kim CH, Lee JK, Lee JH, Suh HW. Role of α-CGRP in the regulation of neurotoxic responses induced by kainic acid in mice. Peptides. 2013; 44: 158-162. doi: 10.1016/j. peptides.2013.04.001
Sardi C, Zambusi L, Finardi A, et al. Involvement of cal-citonin gene-related peptide and receptor component protein in experimental autoimmune encephalomyelitis. J Neuroimmunol. 2014; 271(1-2): 18-29. doi: 10.1016/j.jneuroim.2014.03.008
Engel MA, Khalil M, Siklosi N, et al. Opposite effects of substance P and calcitonin gene-related peptide in oxazo-lone colitis. Dig Liver Dis. 2012; 44(1): 24-29. doi: 10.1016/j. dld.2011.08.030
Yang L, Sakurai T, Kamiyoshi A, et al. Endogenous CGRP protects against neointimal hyperplasia following wire-induced vascular injury. J Mol Cell Cardiol. 2013; 59: 55-66. doi: 10.1016/j.yjmcc.2013.02.002
Li J, Carnevale KA, Dipette DJ, Supowit SC. Renal protec-tive effects of α-calcitonin gene-related peptide in deoxycorti-costerone-salt hypertension. Am J Physiol Renal Physiol. 2013; 304(7): F1000-F1008. doi: 10.1152/ajprenal.00434.2012
Mai TH, Wu J, Diedrich A, Garland EM, Robertson D. Cal-citonin gene-related peptide (CGRP) in autonomic cardiovascu-lar regulation and vascular structure. J Am Soc Hypertens. 2014; 8(5): 286-296. doi: 10.1016/j.jash.2014.03.001
Smillie SJ, King R, Kodji X, et al. An ongoing role of α-calcitonin gene-related peptide as part of a protective network against hypertension, vascular hypertrophy, and oxidative stress. Hypertension. 2014; 63(5): 1056-1062. doi: 10.1161/HYPER-TENSIONAHA.113.02517
Riera CE, Huising MO, Follett P, et al. TRPV1 pain re-ceptors regulate longevity and metabolism by neuropeptide signaling. Cell. 2014; 157(5): 1023-1036. doi: 10.1016/j. cell.2014.03.051
Steculorum SM, Brüning JC. Die another day: a painless path to longevity. Cell. 2014; 157(5): 1004-1006. doi: 10.1016/j. cell.2014.05.013
Bray N. Neuroendocrinology: a long pain-free life. Nat Rev Drug Discov. 2014; 13(7): 495. doi: 10.1038/nrn3778
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content published in Neuro (NEURO) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.